FDA Approves Over-the-Counter Fixed-Dose Combination of Acetaminophen and Naproxen for Pain Relief
核心洞察
The FDA approved a nonprescription fixed-dose pill combining 325 mg acetaminophen (Tylenol) and 110 mg naproxen sodium for up to 12 hours of pain relief.
The combination pill is indicated for adults and children aged 12 and older for headaches, back pain, muscle aches, toothaches, menstrual cramps, and minor arthritis pain.
The approval aligns with "The Great Healthcare Plan," a federal initiative to expand over-the-counter availability of verified safe pharmaceutical drugs.
The U.S. Food and Drug Administration on Friday approved a nonprescription, fixed-dose pill that combines Kenvue (搜索)'s Tylenol (acetaminophen) with the nonsteroidal anti-inflammatory drug (NSAID) naproxen sodium, offering a new over-the-counter option for pain management with up to 12 hours of relief.
The approval was announced on July 24, with the FDA noting that the decision aligns with "The Great Healthcare Plan," a federal effort aimed at making more verified safe pharmaceutical drugs available for over-the-counter purchase.
Indications and Dosing
The combination pill is approved for use in adults and children aged 12 and older. It is indicated for a range of common pain conditions, including headaches, back pain, muscle aches, toothaches, menstrual cramps, and minor arthritis pain. Each pill contains 325 milligrams of acetaminophen and 110 milligrams of naproxen sodium, delivering a fixed-dose dual-mechanism approach to analgesia.
Regulatory and Policy Context
The FDA explicitly tied the approval to the broader federal initiative known as "The Great Healthcare Plan," which seeks to expand consumer access to safe and effective medications without a prescription. This regulatory milestone reflects an ongoing push to transition certain validated pharmaceutical products from prescription-only to over-the-counter status, potentially reducing barriers to timely pain management.
Ongoing Litigation and Safety Considerations
The approval comes amid ongoing scrutiny of acetaminophen. U.S. health officials have raised concerns about an alleged link between Tylenol use during pregnancy and autism, though the FDA and other authorities have emphasized that there is no firm scientific evidence establishing such a link. The debate has triggered significant legal action: the state of Texas sued Kenvue (搜索) over alleged failures to warn pregnant consumers, and a U.S. appeals court this month revived more than 500 private lawsuits making similar claims.
Corporate Developments
Kenvue (搜索), the manufacturer of Tylenol, agreed last November to be acquired by Kimberly-Clark — the maker of Kleenex tissues — in a transaction valued at more than $40 billion. The deal is expected to close this year, positioning the combined entity within a significantly expanded consumer health portfolio.